Arbutus to Present HBV Data at 2018 EASL Liver Meeting
28 mars 2018 17h54 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., March 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Announces Corporate Update and Year-End 2017 Financial Results
14 mars 2018 16h00 HE
|
Arbutus Biopharma Corporation
ARB-1467 Phase II Combination Study Beginning in 1Q18Two New Drug Candidates Planned to Enter Clinical Development in 2H18Over $200M in Cash Available to Fund Development of HBV AssetsCompany to Host...
Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results
12 mars 2018 09h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., March 12, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
M2 Compliance® to Sponsor the 30th Annual ROTH Conference
28 févr. 2018 07h30 HE
|
M2 Compliance
Los Angeles, CA, Feb. 28, 2018 (GLOBE NEWSWIRE) -- M2 Compliance® ("M2"), www.m2compliance.com, a world-leading filing agent registered with the Securities and Exchange Commission and full-service...
Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology
22 févr. 2018 16h35 HE
|
Arbutus Biopharma Corporation
Acuitas has No Further Rights to Use or Sublicense Arbutus LNP TechnologyArbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics VANCOUVER, B.C. and WARMINSTER, Pa.,...
Arbutus Enters Exclusivity Agreement with Roivant Sciences
14 févr. 2018 20h50 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO
13 févr. 2018 21h36 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Consolidates HBV Business Around Warminster, PA Site
08 févr. 2018 08h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Announces Presentations at HepDART 2017
27 nov. 2017 09h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran
16 nov. 2017 13h40 HE
|
Arbutus Biopharma Corporation
VANCOUVER, B.C. and WARMINSTER, Pa., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company,...